Mazen Noureddin, MD, MHSc, did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 and was appointed as the founding director of Fatty Liver Program.

Dr. Noureddin is internationally known for his research in the area of MASLD/MASH and MASH related cirrhosis. He conducted more than 50 investigational clinical studies of novel treatments for MASH. He is an expert in non-invasive testing and biomarkers of NASH and cirrhosis. He has published in all these areas and has been invited to consensus panels on these topics by multiple international societies including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of Liver Diseases (EASL), Asian Pacific Association for the Study of the Liver (APASL) and Latin American Association for the Study of the Liver (ALEH). He has given invited lectures on MASLD/MASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is chair of the AASLD MASLD special interest group and has served on the editorial board for major GI journals including “Gastroenterology”, “Hepatology” and  “Clinical Gastroenterology and Hepatology (CGH)”. He is an Associate Editor for “Clinical Gastroenterology and Hepatology (CGH)”. Dr. Noureddin has been funded by the National Cancer Institute and has served as a reviewer on NIH study sections. He has published >240 papers in many journals including: The New England Journal of Medicine, The Lancet, Nature Medicine, Lancet Gastroenterology and Hepatology, Science Translational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology and others.

In May 2022, Dr. Noureddin moved to Houston, He is currently a Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital (currently ranked #5 in GI and GI surgery by US News). He has also established the Houston Research Institute which is State of the Art facility that offers patients with liver disease access to new innovative non-invasive diagnostic tests and breakthrough therapies. Dr. Noureddin also serves as the Chief Scientific Officer and Board Member of Summit Clinical Research, the leading integrated research organization that brings together experienced research sites that have proven to be successful in the NASH/MASH research space.